Boehringer Ingelheim has a long-term commitment to deliver tomorrow's cancer therapies by discovering and developing novel treatment options that combine ground-breaking science with the intent of high therapeutic value for patients. It runs an extensive and diverse study programme involving investigators and patients from around the world. This is supported by a significant financial investment, with the aim of developing treatments, which will make a difference to the lives of patients and their families.
The current focus of research includes compounds in signal transduction inhibition, angiogenesis inhibition and cell-cycle kinase inhibition. Boehringer Ingelheim's first oncology compound is available to patients with Epidermal Growth Factor Receptor (EGFR) mutation positive non-small cell lung cancer (NSCLC). Two investigational compounds are in Phase III clinical development: one in NSCLC and colorectal cancer, the other one in acute myeloid leukemia.
More than 400 employees around the world (including 250 highly skilled scientists in Vienna, Austria at the Boehringer Ingelheim cancer research centre) are dedicated to the discovery and development of new cancer treatments. They work with the Research Institute of Molecular Pathology (IMP) in Austria and experts in universities and hospitals around the world.
Lung cancer is the single most common cancer worldwide, causing 1.5 million deaths every year. Survival is poor, with fewer than one in ten people in the UK surviving more than five years, and more than two thirds of people with the disease are diagnosed at a stage where curative treatment is no longer an option. Cancer Research UK is determined to improve the outlook for lung-cancer patients, and more research is at the heart of how we plan to achieve this goal. We will speed up progress by increasing the amount of lung cancer research we support two- to three-fold over the next five years. We'll be tackling lung cancer on all fronts – working tirelessly to reduce the influence of the tobacco industry and cut smoking rates, looking for innovative new ways to spot the disease earlier when people can be cured, and developing more effective and tailored treatments to give lung-cancer patients a better outcome in the future.